Overview

• Cofepris approved Apretude, a long-acting cabotegravir injection for HIV PrEP, for adolescents aged 12 and up (minimum 35 kg) and adults as part of a bulk authorization of over 200 health inputs.
• The prevention regimen starts with two cabotegravir injections spaced one month apart followed by maintenance doses every two months, with an optional four-week oral lead-in to verify tolerance.
• FDA trial results cited by Mexican media showed cabotegravir PrEP reduced HIV acquisition risk by about 69% in high-risk men and trans women and by up to 90% in cisgender women compared with daily Truvada.
• Healthcare providers must confirm a negative HIV test before each injection to prevent the emergence of drug resistance and ensure patient safety.
• Press reports also identify a bi-monthly injectable ART combining cabotegravir and rilpivirina as newly available for people living with HIV, offering an alternative to daily oral therapy.